ABI
ACHN

Adamant Biomedical Investments’s Achillion Pharmaceuticals ACHN Stock Holding History

Adamant Biomedical Investments’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.23M Buy
100,000
+20,000
+25% +$244K 0.29% 78
2014
Q3 		$798K Buy
+80,000
New +$743K 0.2% 81

Other funds holding ACHN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adamant Biomedical Investments's ACHN Position: Q4 2014 in Review

Adamant Biomedical Investments increased its Achillion Pharmaceuticals (ACHN) stake by 25% in Q4 2014, buying an estimated $244K and bringing the position to 100,000 shares worth $1.23M. The position accounts for 0.29% of the portfolio, ranked #78.

Adamant Biomedical Investments first reported a position in ACHN in Q3 2014 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold ACHN as of Q4 2014.

  • Adamant Biomedical Investments held 100,000 shares of Achillion Pharmaceuticals worth $1.23M as of Q4 2014.
  • Adamant Biomedical Investments bought 20,000 Achillion Pharmaceuticals shares in Q4 2014, an estimated $244K.
  • Achillion Pharmaceuticals made up 0.29% of Adamant Biomedical Investments's portfolio in Q4 2014, its #78 holding.
  • Adamant Biomedical Investments first reported a position in Achillion Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.